Checkpoint Therapeutics’ cosibelimab could become the ninth PD-(L)1 drug to reach the US market, but who will be around to launch it?
Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.
Imetelstat survives a US clinical hold and a terminated alliance with J&J to score in its pivotal Imerge study.
The purchase sets up another showdown with the group’s old rival, Bristol Myers Squibb, in LSD1 inhibition.